FBR & Co Reaffirms Outperform Rating for RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “outperform” rating restated by stock analysts at FBR & Co in a report released on Wednesday. They presently have a $36.00 target price on the stock. FBR & Co’s price objective would indicate a potential upside of 156.59% from the stock’s current price.
RDHL has been the subject of several other reports. Zacks Investment Research upgraded shares of RedHill Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. HC Wainwright set a $33.00 target price on shares of RedHill Biopharma and gave the company a “buy” rating in a research note on Friday, October 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. RedHill Biopharma currently has a consensus rating of “Buy” and a consensus target price of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) traded up 1.07% during mid-day trading on Wednesday, reaching $14.18. The company’s stock had a trading volume of 11,635 shares. The firm’s market capitalization is $180.57 million. The company has a 50 day moving average of $14.63 and a 200-day moving average of $12.81. RedHill Biopharma has a 12 month low of $8.10 and a 12 month high of $16.54.
RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.52. Equities research analysts forecast that RedHill Biopharma will post ($2.06) EPS for the current year.
A number of large investors have recently modified their holdings of the company. Oppenheimer & Co. Inc. bought a new stake in shares of RedHill Biopharma during the second quarter valued at about $142,000. Van ECK Associates Corp increased its stake in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the period. Ingalls & Snyder LLC bought a new stake in shares of RedHill Biopharma during the second quarter valued at about $451,000. Finally, Royal Bank of Canada increased its stake in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the period. Hedge funds and other institutional investors own 15.30% of the company’s stock.
RedHill Biopharma Company Profile
Receive News & Stock Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related stocks with our FREE daily email newsletter.